nach oben

Erschienen in:

01.08.2007 | Updates

Update in Addiction Medicine for the Generalist

verfasst von: Adam J. Gordon, MD, MPH, Lynn E. Sullivan, MD, Daniel P. Alford, MD, MPH, Julia H. Arnsten, MD, MPH, Marc N. Gourevitch, MD, MPH, Stefan G. Kertesz, MD, MSc, Hillary V. Kunins, MD, MPH, MS, Joseph O. Merrill, MD, Jeffrey H. Samet, MD, MA, MPH, David A. Fiellin, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Excerpt

Generalist physicians can play a critical role in identifying and treating patients with addictions to alcohol, nicotine, and/or other drugs of abuse. In the United States, nicotine dependence and unhealthy alcohol use are the first (18.1%) and third (3.5%) leading causes, respectively, of preventable deaths.1 Primary care physicians have not traditionally treated substance use despite the harmful effects that addiction can cause in their patients. The objective of this paper is to present recent evidence on recognizing and treating addiction disorders that is relevant for generalist physicians. We conducted an electronic database (PubMed) search to systematically identify recent (January 1, 2003, to June 1, 2006), human subject, English language, peer-reviewed, research articles or publications that impact generalist care for patients with addiction disorders. The search strategy and consensus deliberations were used to identify important articles in the categories of screening strategies for patients with alcohol problems and use of specific pharmacotherapies for patients with alcohol, nicotine, and opioid dependence. …

Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238–45.PubMedCrossRef

Substance Abuse and Mental Health Services Administration Office of Applied Studies. Results from the 2004 Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2005. DHHS publication no. SMA 05-4062, NSDUH series H-28.

Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend. 2004;74(3):223–34.PubMedCrossRef

Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med. 2005;352(6):596–607.PubMedCrossRef

Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(7):557–68.PubMed

Pettinati HM, Weiss RD, Miller WR, Donovan D, Denise B, Rounsaville BJ. COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004. DHHS publication no. (NIH) 04-5289.

Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA. 2006;295(17):2003–17.PubMedCrossRef

Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl. 2005;(15):170–8.

Miller WR. Combined behavioral intervention manual. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004. NIH publication no. 04-5288.

10.

Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–25.PubMedCrossRef

11.

Miller WR, Walters ST, Bennett ME. How effective is alcoholism treatment in the United States? J Stud Alcohol. 2001;62(2):211–20.PubMed

12.

Tucker JA, Roth DL. Extending the evidence hierarchy to enhance evidence-based practice for substance use disorders. Addiction. 2006;101(7):918–32.PubMedCrossRef

13.

Agency for Healthcare Research and Quality. The Guide to Clinical Preventive Services, 2005. Recommendations of the U.S. Preventive Services Task Force. Available at http://www.preventiveservices.ahrq.gov. Accessed December 1, 2006.

14.

McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635–45.PubMedCrossRef

15.

National Institute on Alcohol Abuse and Alcoholism. Helping Patients Who Drink Too Much: A Clinician’s Guide. Rockville, MD: U.S. Department of Health & Human Services; 2005. NIH publication no. 05-3769.

16.

Fleming MF. In search of the Holy Grail for the detection of hazardous drinking. J Fam Pract. 2001;50(4):321–2.PubMed

17.

Gordon AJ, Maisto SA, McNeil M, et al. Three questions can detect hazardous drinkers. J Fam Pract. 2001;50(4):313–20.PubMed

18.

Canagasaby A, Vinson DC. Screening for hazardous or harmful drinking using one or two quantity–frequency questions. Alcohol Alcohol. 2005;40(3):208–13.PubMed

19.

Williams R, Vinson DC. Validation of a single screening question for problem drinking. J Fam Pract. 2001;50(4):307–12.PubMed

20.

Vinson DC. Screening question for alcohol abuse. Am Fam Physician. 2002;66(2):209.PubMed

21.

Taj N, Devera-Sales A, Vinson DC. Screening for problem drinking: does a single question work? J Fam Pract. 1998;46(4):328–35.PubMed

22.

National Center For Chronic Disease Prevention and Health Promotion, Center for Disease Control. Percentage of adults who were current, former, or never smokers, overall and by sex, race, Hispanic origin, age, and education, National Health Interview Surveys, selected years—United States, 1965–2000. Available at: http://www.cdc.gov/tobacco/research_data/adults_prev/adstat1print.htm. Accessed October 5, 2006.

23.

Centers for Disease Control and Prevention. Smoking-attributable mortality and years of potential life lost—United States, 1984. MMWR Morb Mortal Wkly Rep. 1997;46(20):444–51.

24.

Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;(1):CD003041.

25.

Friedenreich CM. Methods for pooled analyses of epidemiologic studies. Epidemiology. 1993;4(4):295–302.PubMedCrossRef

26.

Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.PubMedCrossRef

27.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef

28.

National Cholesterol Education Program Expert Panel on Detection EaToHBCiAATPI. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.

29.

Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38.PubMedCrossRef

30.

Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39.PubMedCrossRef

31.

The Tobacco Use and Dependence Clinical Practice Guideline Panel SaCR. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA. 2000;283(24):3244–54.CrossRef

32.

Thorndike AN, Rigotti NA, Stafford RS, Singer DE. National patterns in the treatment of smokers by physicians. JAMA. 1998;279(8):604–8.PubMedCrossRef

33.

Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55.PubMedCrossRef

34.

Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56–63.PubMedCrossRef

35.

Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64–71.PubMedCrossRef

36.

Johnston LD, O’Malley PM, Backman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings. Bethesda, MD: National Institute on Drug Abuse; 2005.

37.

Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35(12):1747–59.PubMedCrossRef

38.

Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manage. 2004;28(2):176–88.PubMedCrossRef

39.

Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–76.PubMedCrossRef

40.

Institute of Medicine. Improving the Quality of Healthcare for Mental and Substance-use Conditions: The Quality Chasm Series. Washington, DC: The National Academies Press; 2005.

41.

Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: The National Academies Press; 2001.

Titel: Update in Addiction Medicine for the Generalist
verfasst von: Adam J. Gordon, MD, MPH
Lynn E. Sullivan, MD
Daniel P. Alford, MD, MPH
Julia H. Arnsten, MD, MPH
Marc N. Gourevitch, MD, MPH
Stefan G. Kertesz, MD, MSc
Hillary V. Kunins, MD, MPH, MS
Joseph O. Merrill, MD
Jeffrey H. Samet, MD, MA, MPH
David A. Fiellin, MD
Publikationsdatum: 01.08.2007
Verlag: Springer-Verlag
Erschienen in: Journal of General Internal Medicine / Ausgabe 8/2007
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-007-0133-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Update in Addiction Medicine for the Generalist

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2007

Measuring Quality of Care in Patients With Multiple Clinical Conditions: Summary of a Conference Conducted by the Society of General Internal Medicine

Impact of Student Ethnicity and Primary Childhood Language on Communication Skill Assessment in a Clinical Performance Examination

Spirituality and HIV Disease Progression

Primary Care Resident Perceived Preparedness to Deliver Cross-cultural Care: An Examination of Training and Specialty Differences

Lead Poisoning in an Adult: Lead Mobilization by Pregnancy?

Clinical Oversight: Conceptualizing the Relationship Between Supervision and Safety

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Innere Medizin